leadf
logo-loader
viewAstraZeneca PLC
(
LSE:AZN
)

AstraZeneca vaccine should not be offered to healthy under 30s, UK government says

The authorities stressed that the jab's benefits continue to outweigh the risks

AstraZeneca - AstraZeneca should not be offered to healthy under 30s, UK government says

The UK has announced a “change of course” with the vaccination programme in relation to the AstraZeneca PLC (LON:AZN)/Oxford University COVID-19 jab.

Professor Lim Wei Shen, chair of COVID-19 immunisation at the Joint Committee on Vaccination and Immunisation (JCVI), said that those who are aged 18 to 29, and don’t have any underlying issues making them vulnerable to the virus, should be offered another vaccine.

READ: AstraZeneca COVID-19 vaccine fine for use, says EU regulator

He added that those who have already received the first dose of the AstraZeneca jab should go for the second dose as scheduled.

The alternatives currently approved in the UK are inoculations developed by Pfizer and Moderna.

Jonathan Van-Tam, deputy chief medical officer at Department of Health and Social Care, said in a press briefing on Wednesday that this decision should not affect the national rollout.

“The effect on the timing of our overall program should be zero, or negligible,” he said.

June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA), said the blood clot cases have been reported in an “extremely small” number of people.

Up to March 31, thrombosis was reported in 79 people, with 19 deaths including three people aged under 30.

Over 20mln doses of the jab have been administered in the UK.

Raine stressed the benefits continue to outweigh the risks in most people.

Professor Sir Munir Pirmohamed, chair of the Commission on Human Medicines, said that people who have experienced cerebral or other major blood clots with low levels of platelets with the first dose should not receive the second one.

Pregnant women should continue discussing with their doctor on which vaccine to receive while those with history of blood disorders should take the AstraZeneca vaccine only if the benefits outweigh the risks.

Earlier on Wednesday, the European Medicines Agency (EMA) said the bloc should continue using the jab without limitations to age groups.

Shares in the FTSE 100 pharma company dipped 1% to 7,115p before close.

Quick facts: AstraZeneca PLC

Follow
LSE:AZN

Price: 8628 GBX

Market Cap: £133.64 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE up as government keep cap on gas prices with energy market in focus

FTSE 100 jumped back near the 7,000 mark even though government borrowing was higher than expected in August. London’s leading index added 64 points to 6,968 in early trading.   The UK government has decided to keep the cap on how much energy suppliers can charge customers to protect the...

1 hour, 19 minutes ago

3 min read